Daniel Goor

Itamar Medical Ltd. engages in the research, development, marketing, selling, and leasing of non-invasive medical devices based on peripheral arterial tone signals. It develops and markets the WatchPAT and EndoPAT products. The WatchPAT diagnoses sleep apnea, a substantial risk factor in cardiac disease. The EndoPAT diagnoses endothelial malfunction, which is a predictor of cardiovascular disease. The company was founded by Yaron Giora , Martin Gerstel, Peretz Lavie, and Daniel Gur in 1995 and is headquartered in Caesarea, Israel.

New N.I. Medical (2011) Ltd. provides a non-invasive cardiac output monitoring system called nicas, which helps manage hypertension, dialysis, and heart failure. The private company is based in Raanana, Israel and was founded in 2011. The system is easy to use, cost-effective, and provides accurate assessment of cardiovascular, respiratory, and fluid status. The Israeli company's flagship solution, nicas, is based on advanced, proprietary patented technology and is designed to be the preferred solution for various challenges in cardiovascular disease management. The CEO is Eyal Karev.